|
|
|
|
|
|
|
10.02.26 - 13:03
|
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting (Business Wire)
|
|
|
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company's KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 – March 2, 2026 in Philadelphia, PA.
Details of the presentations are as follows:
Abstract Title: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases
Date: Friday, February 27, 2026
Time: 2:45 – 3:45 PM EST
Poster Number: 104
Session: Allergic Skin Diseases
Location: Convention Center, Level 2, Hall E
Presenter: Tessa Cressey, Ph.D.
Abstract Title: EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharm...
|
|
|
|
|
09.02.26 - 22:03
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 (Business Wire)
|
|
|
Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV)
Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026
On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 for EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate
On Track to File an IND in 2H 2026 for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate
Strong Financial Position of $241.9 Million Supported by Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal first q...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.11.25 - 22:06
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 (Business Wire)
|
|
|
Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models
Announces EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate with Plans to File an Investigational New Drug Application in Q1 2026
Reported Positive Topline Data for RSVHR, a Phase 2b Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV)
Strong Financial Position Ending Fiscal 2025 with $188.9 Million in Cash, Cash Equivalents and Marketable Securities; Further Strengthened by Gross Proceeds of $74.8 Million Upsized Public Offering in October 2025 and Continuing Retained Royalties, Expected to Fund Operations into Fiscal 2029
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
